AHR and breast cancer: In this regard, studies by Kado and colleagues demonstrated that 2,3,7,8-tetrachlorodibenzio-p-dioxin (TCDD)-mediated activation of AhR signaling increased IDO2 expression in wildtype MCF7 breast cancer cells but not in CRISPR-cas9 AhR-knockout MCF-7 cells.